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ABSTRACT
Background: An open-label, multi center and non-comparative study was conducted to evaluate the
efficacy and safety of a more affordable in-Asia-manufactured interferon α -2b product in combination with 
ribavirin to treat naïve chronic hepatitis C patients.
Method:  Thirty  chronic  naïve  hepatitis  C  patients  were  treated  with  in-Asia-manufactured  interferon
α -2b subcutaneously 3 MIU thrice weekly and ribavirin 800-1,200 mg daily for 48 weeks. Follow-up was 
done until 24 weeks after the end of treatment. Efficacy was assessed by examining serologic and biochemical 
parameters at pre and post-treatment. Safety was assessed by evaluating clinical symptoms and laboratory 
parameters.
Results:  The  virological  response  and  sustained  virological  response  rates  of  all  Hepatitis  C  Virus
(HCV) genotypes were 83.3% and 76.7% respectively. Post-treatment, 80% patients had significant alanine 
transaminase (ALT) decreased into normal level and remained normal in 76.7% patients at 24th week follow 
up period. At that time, the ALT level and sustained virological response were lower in HCV genotypes 1 and 
4 than in non-1 and non-4 genotypes. The most frequent adverse event was flu-like syndrome.
Conclusion:  The  efficacy  and  safety  study  on  combination  therapy  of  in-Asia-manufactured  interferon
α -2b and ribavirin has shown a good result based on the current standard of interferon alpha and ribavirin 
combination therapy.
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INTRODUCTION
Hepatitis C Virus (HCV) infection is the most 
common chronic blood-borne infection, with an 
estimation of 170 million people infected worldwide.1
World Health Organization (WHO) estimates that three
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to four million people are newly infected by this virus 
every year and 70% of them will develop chronic 
hepatitis.2 Approximately, 20% patients with chronic 
HCV infection will progress to get cirrhosis after an 
average 20-years period, and 5% will develop 
hepatocellular carcinoma.3-5 Hepatitis C is the leading 
cause of chronic liver disease and liver cancers world-
wide, and it is also responsible for two thirds of liver 
transplants.6,7 Mortality due to chronic HCV infection 
is expected to increase two to threefold over the next 
10-20 years. Thus, hepatitis C is considered as an 
important health care problem which needs serious
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attention in addition to its limitation of treatment 
methods.2
The primary goal of therapy for chronic HCV 
infection is viral eradication. Previously, treatment 
of hepatitis C was based on the use of various 
preparations of interferon α alone, and then the 
treatment developed using combination of interferon 
with ribavirin. Pilot studies of patients who have 
relapsed and of previously untreated patients suggest 
that combining interferon with ribavirin is more 
effective than using interferon alone,8,9 and in a 
small, placebo-controlled study of previously 
untreated patients, treatment with interferon and 
ribavirin for six months was more effective than 
interferon alone.10
The current standard of interferon alpha and 
ribavirin combination therapy, based on several 
studies of combination therapy with Interferon (IFN) 
alpha and ribavirin, is demonstrated Sustained 
Virologic Response (SVRs) of approximately 
40%.10-13 Currently, pegylated interferon α has been 
used as standard treatment for chronic hepatitis C 
because some studies found that pegylated interferon 
α was more effective than conventional interferon 
for hepatitis C treatment.13-15 However, it has been 
reported that efficacy of most in Western-
manufactured interferon α -2b was still comparable 
with the pegylated interferon.13,16 Therefore,
interferon α is still used especially for patients who
cannot   afford   pegylated   interferon   α since
the treatment cost of in-Western-interferon α is about
half or one third of the pegylated interferon α .
Since for some population the in Western-
manufactured-interferon and pegylated interferon is 
still considered expensive, therefore, a more affordable 
product of interferon α -2b has been developed in 
China. This study was conducted to investigate the 
efficacy and safety of in-Asia-manufactured interferon 
α -2b in combination with ribavirin for treatment of 
naïve chronic hepatitis C patients.
HYPOTHESIS
We hypothesized that the efficacy and safety of 
in-Asia-manufactured interferon α -2b in 
combination with ribavirin to treat naïve chronic 
hepatitis C patients met the current standard of 
interferon alfa and ribavirin combination therapy.
METHODS
Selection of Subjects
The eligibility criteria were patients aged 18-65 
years with positive HCV Ribonucleic Acid (RNA) 
serum; Alanine Transaminase (ALT) level 1.5 - 10 
times of upper normal limit; had never been
treated with any antiviral agents; had normal levels 
of albumin, bilirubin, creatinine, Thyroid 
Stimulating Hormone (TSH) and prothrombine time; 
negative hepatitis B surface antigen (HBsAg), 
hemoglobin level ≥ 12 g/dL (male) or ≥ 11 g/dL 
(female), leukocytes count ≥ 3,000/µL, platelet 
count ≥ 100,000/ µL, and neutrophils count ≥
1,500/µL. Patients with hepatocellular carcinoma, 
history of moderate to severe psychiatric conditions, 
seizure disorder, cardiovascular disease, chronic 
lung disease, diabetes mellitus, hyperuricemic 
condition, pregnancy, breastfeeding, malignancy, 
drugs or alcohol abuse, and other conditions, in 
which compliance and safety issue could not be 
determined, and those who were unable to practice 
contraception, were excluded from this study. The 
study was approved by Ethics Committee of Cipto 
Mangunkusumo hospital. Before treatment, written 
informed consent was obtained from each patient 
and the study was carried out in accordance to the 
provisions of the Declaration of Helsinki.
Study Design
This multicenter, prospective, open-label 
uncontrolled trial of efficacy and safety was 
conducted at four hospitals in Jakarta. The analysis 
was based on 30 patients who had completed study 
protocol. The trial began in January 2004, and the 
trial was completed in October 2005. Duration of 
treatment was assigned as follows: 12 month-
treatment for patients with genotype 1 and 4; 12 
month-treatment for patients with genotype 2 and 3 
with HCV RNA titer ≥ 2 x 106 copy/mL, and 6 
month- treatment for patients with genotype 2 and 3 
with HCV RNA titer < 2 x 106 copy/mL. The study 
medications were given in open-label fashion.
The interferon α -2b was administered 
subcutaneously at the dose of 3 Million International 
Units (MIU) thrice weekly and ribavirin twice daily
orally at a total dose of 800 mg for patients with body 
weight ≤ 55 kg, 1,000 mg for 56-74 kg of body weight, 
and 1,200 mg for body weight ≥ 75 kg. The dose of 
interferon alpha-2b would be reduced to 50% if 
leukocytes count ≤ 1,500/µL, neutrophils count ≤
750/µL or platelet count ≤ 50,000/µL. Ribavirin dose 
was reduced to 400-600 mg/day if hemoglobin level 
was < 10 g/dL. Ribavirin treatment was temporarily 
discontinued if indirect bilirubin level was > 5 mg/dL 
and would be reinstated at a dose of 400-600 mg/day 
when indirect bilirubin level was returned to < 2 
mg/dL. Full dose of ribavirin would be administered if 
bilirubin level was < 2 mg/dL for more than 4 weeks. 
Combination therapy would be discontinued for any of 
the followings: hemoglobin level ≤ 8.5 g/dL, 
leukocytes count ≤ 1,000/µL, neutrophils
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Table  1.  Trial  procedure  scheme  for  48  week-treatment
*
Table  2.  Trial  procedure  scheme  for  24  weeks  treatment
*
count ≤ 500/µL, platelet count ≤ 25,000/µL, AL T 
level increased 2-fold from baseline level or 10 
times of upper normal limit, or indirect bilirubin 
level was > 4 mg/dL for more than 4 weeks.
Hematology parameters were evaluated before 
treatment, every 2 weeks for the first month and 
every 4 weeks during and after treatment. Hepatitis 
C Virus RNA serum and TSH level were measured 
before treatment, at 24th week and 48th week of 
treatment, and 24 weeks after the end of treatment. 
Potential adverse events and all adverse events 
occurred were tightly monitored and recorded 
anytime during and within one month after 
treatment. Therapy would have to be discontinued if 
life threatening events occurred.
Assessment of Efficacy and Safety
The primary end point was serologic 
improvement, based on Virologic Response (VR), 
defined as no HCV RNA detected in blood at the 
end of therapy, and Sustained Virologic Response 
(SVR), defined as the absence of serum HCV RNA 
by 24 weeks after treatment was completed. 
Secondary endpoint was Biochemical Response 
(BR), which was defined as the ALT level 
normalization at the end of treatment. Breakthrough 
was defined when HCV RNA serum was 
undetectable at 24th week of treatment, but became 
positive at the end of treatment. Safety was assessed 
by clinical symptoms and laboratory parameters.
Statistical Method
Sample size was determined based on reference 
by McHutchinson et al,11 that indicated virologic 
response rate after treatment with interferon and 
ribavirin for 24 weeks was 31 percent. VR and SVR 
were presented descriptively. The biochemical 
responses before and after treatment were analyzed 
using Student t-test.
RESULTS
Characteristics of the Patients
Genotypes of HCV in this study were 1, 2, 3, 4, 
and 10. Baseline mean viral load in this study (0.82 
± 1.02 x 106 IU/mL) categorized as high (expressed 
in IU/mL and it was categorized as high when the 
viral load more than 800,000 IU/mL).
Virologic Response Rate
At the end of treatment, virological response rate 
in HCV genotype non-1 and non-4 (100%) were 
higher than genotype 1 or 4 (78.3%). Virological 
response rate of all HCV genotypes was 83.3% 
(table 4).
Sustained Virological Response Rate
At 24th week of follow up, we evaluated the 
sustained virological response rate . The genotype of 
non-1 and non- 4 (100%) were higher than genotype 
1 or 4 (69.6%). Sustained virological response rate 
of all HCV genotypes was 76.6%. There were no 
breakthrough cases during the study (table 4).
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Table 3. Baseline characteristics of the patients
Characteristic Mean ± SD Number
(%)
Age  (years) 39 ± 14
Sex
Female 8 (26.7)
Male 22 (73.3)
Body mass index  (kg/cm
2
) 23.74 ± 4.47
Viral load (x 10
6
IU/mL) - (high) 0.82 ± 1.02
ALT (U/L) (1.5-10 times > normal) 102.77 ± 53.66
HCV genotype 1 or 4 23 (76.6)
1 14 (46.7)
4 9 (30)
HCV genotype (non 1 and non 4) 7 (23.3)
2 3 (10)
3 2 (6.7)
10 1 (3.3)
Undetermined 1 (3.3)
Source of infection
Drug abuse 11 (36.7)
Transfusion 7 (23.3)
Operation 6 (20)
Unknown 6 (20)
Biochemical Response Rate
The ALT level decreased significantly since the 
fourth week of therapy (102.77 ± 53.66 vs. 36.43
± 26.02; p = 0.000) (table 5). Serum ALT levels at the 
end of treatment were normal in 80% patients with all 
HCV genotype and remained normal in 76.67%
patients throughout follow up period at 24th week. At 
the end of therapy, BR rate was higher in patients with 
genotypes non-1 and non-4 as compared to the types 1 
and 4 (85.7% vs. 78.2%). At 24th week of follow up, 
BR rates also were higher in patients with genotypes 
non-1 and non-4 as compared to the types 1 and 4 
(85.7% vs. 69.6%, respectively). Specifically, the BR 
at 24th week follow-up period was higher in type 4 
(77.8%) than in type 1 (71.4%).
Safety
There was no drop-out case. Ten patients (33.3%) 
met the criteria for dose reduction or drug 
discontinuation. Six of them had anemia, three had 
increased direct bilirubin level, and one had 
neutropenia. However, only eight of them were 
considered for dose adjustment or temporary 
treatment discontinuation. Mean hemoglobin level 
decreased significantly at 4th week of treatment. One 
patient had hemoglobin level below 8.5 g/dL, 
leading to adjustment of ribavirin dose while 
interferon α -2b was reinstated at full dose.
There were no significant changes in platelet 
count during this study. Significant decrease of 
leukocytes count was observed but not followed by 
dose adjustment or discontinuation. One patient 
showed neutrophil count below 750/µL and required 
a dose reduction of interferon α -2b.
Direct bilirubin level increased significantly 
between the 2nd and 12th week of treatment, and three 
patients (10%) showed a level of more than 2.5 times 
of upper normal limit. Two of them did not require 
dose adjustment and the direct bilirubin level returned 
to normal at following months; meanwhile, both drugs 
were temporarily discontinued in one patient due to 
jaundice observed at second and third week, and then 
full dose of combination therapy was reinstated at the 
fourth week. There was statistically but not clinically 
significant change on albumin level during treatment. 
The TSH level increased above normal level during 
treatment in one patient. Flu like syndrome was the 
most symptoms observed during treatment 100%. 
Other symptoms were similar to previous reports of
Table 4. Virologic response and sustained virologic response 
Variable n
Number (%)
VR - 24 week VR - 48 weeks SVR - 24 weeks
     Age (years)
< 50 20 7 (85) 17 (85) 15 (75)
> 50 10 8 (80) 8 (80) 8 (80)
     Sex
Male 22 19 (86.4) 19 (86.4) 18 (81.8)
Female 8 6 (75) 6 (75) 5 (62.5)
    Genotype
1 or 4 23 18 (78.3) 19 (86.4) 16 (69.6)
1 14 11 (78.6) 11 (78.6) 10 (71.4)
4 9 7  (77.8) 7 (77.8) 6 (66.7)
Non 1 & non 4 7 7 (100) 7 (100) 7(100)
All 30 25 (83.3) 25 (83.3) 23 (76.7)
Viral load (U/mL)
< 800.000                          19 17 (89.5) 17 (89.5) 17 (89.5)
> 800.000                              11 8 (72.7) 8 (72.7) 6 (54.5)
IDUs 11 9 (81.8) 9 (81.8) 8 (72.7)
With VL <  800,000 5 5 (100) 5 (100) 5 (100)
With VL > 800,000 6 4 (66.7) 4 (66.7) 3 (50)
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Table 5. Hematological examination, ALT, albumin, direct bilirubin level
Variable
Hemoglobin                     
(g/dL)
Leukocyte
(103/uL)
Platelet
(103/uL)
ALT
(U/L)
Albumin
(g/dL)
Bilirubin
(mg/dL)
Mean ± SD p* Mean ± SD p* Mean ± SD p* Mean ± SD p* Mean ± SD p* Mean ± SD p*
Baseline 14.6 ± 1.6 6.6  ± 1.9 212.0 ± 67.9                  102.77 ± 53.66 4.3 ± 0.2 0.25 ± 0.1
Week 2 14.2 ± 1.5   0.124      5.7 ±  1.6 0.001      213.2 ± 66.4    0.825     56.10 ± 48.39 0.000 4.2 ± 0.2 0.023 0.38 ± 0.2 0.000
Week 4 13.3 ± 1.8   0.000      5.6 ± 2.4 0.200     225.3 ± 76.3    0.067      36.43 ± 26.02* 0.000 4.3 ± 0.3 0.103 0.33 ± 0.2 0.004
Week 12   12.7 ± 1.8   0.000       4.8 ± 1.3 0.000     260.2 ± 169.7  0.162      33.73 ± 43.93 * 0.000 4.4 ± 0.3 0.385 0.30 ± 0.1 0.015
Week 24   12.7 ± 1.7 0.000       4.4 ± 1.3 0.000     202.2 ±  73.8    0.176      30.53 ± 33.28 * 0.000 4.4 ± 0.2 0.301 0.26 ± 0.1 0.570
Week 48  12.7 ± 1.8   0.000       4.4 ± 1.4 0.000     201.9 ± 74.5    0.161      30.33 ± 31.92 0.000 4.3 ± 0.3 0.078 0.27 ± 0.1 0.375
Follow 
up  w-24
14.7 ± 1.4   0.378      7.0 ± 2.0 0.183     225.5 ± 65.6    0.087      40.9 ± 54.4 0.000 4.5 ± 0.2 0.016 0.19 ± 0.1 0.013
* Student t-test, compare to baseline 95% confidence interval
other studies on interferon, such as abdominal discomfort, 
dermatologic symptoms, sore throat and psychiatric 
symptoms.
DISCUSSION
The current standard of interferon alpha and ribavirin 
combination therapy, based on previous several studies 
using combination therapy with in-Western-manufactured 
interferon alfa and ribavirin, is demonstrated SVRs of 
approximately 40%.10-13 Patients characteristics in this 
study were similar to the prior trials in the United 
States.11,17,18 The proportion of patients with HCV 
genotype 1 or 4 (76.6%) was almost similar to the 
proportions in the prior trials (72%).11,17,18 It was equal to 
McHutchinson et al,11 trial which had approximately 5 to 
6 x 106 copies/mL (expressed in copies/mL, categorized 
high if viral load more than 2 x 106 cop-ies/mL). Average 
age of patients in this study (39 ± 14 years old) was 
slightly younger than average patients age in 
McHutchinson et al trial (44 ± 8 years old). 11 Mean body 
mass index was the same as that in McHutchinson et al 
trial11, which was catego-rized as normal body mass 
index. ALT level was the same as patients in 
McHutchinson et al trial11, i.e. 1.5 - 10 times upper 
normal limits.
Our study with similar baseline patients 
characteristic and treatment procedure with that 
studies10-13 showed SVR rate 76.7%. The SVR rate 
from our study showed good result if we compare to 
SVR rate from other previous similar studies.10-13 In 
this study, the virological response at the end of 
treatment was 83.3%. Virological response rate in 
HCV genotype non-1 and non-4 (100%) were higher 
than genotype 1 or 4 78.3% as well as sustained 
virological response rate in genotype non-1 and non-
4 (100%) were also higher than genotype 1 or 4 
(69.6%). 
SVR from other trial with different characteristic 
of patients, such as in chronic hepatitis C patient with 
normal ALT level showed SVR of 32% with this
combination  treatment.19  In Japanese population setting, 
but in relapsed case after previous interferon therapy, 
treatment with other interferon α -2b regimen in  
combination  with  ribavirin  produced  virological 
response  of  75%  and  SVR  58.3%  at  the  end  of 
treatment and at 24th  week of follow up respectively.20
We  found  that  SVR  were  higher  in  HCV  type non-1 
and non-4 than in types 1 and 4. These findings are  in  
accordance  with  other  studies.13,14,15,19,20 Interferon 
therapy was more efficacious in types 2 and 3 patients as 
compared with types 1 and 4. In our study, compared to 
the type 4, SVR rate in type 1 was higher. This  result  
was  in  contrast  with  other  studies,  which reported that 
SVR rate for genotype 1 was lower than SVR  for  
genotype  4.13,21   The  VR  at  24th   week  and 48th   week  
of  treatment  were  higher  in  patients  aged below 50 
years old (85% and 85%, respectively) and also in those 
with lower viral load (< 800,000 U/mL). In the  study  by  
Manns  et  al,13  and  Carrat  et  al,22   also showed the 
benefit of pegylated interferon α -2b over interferon α -2b, 
which was not seen in patients infected with   HCV   
genotype   2   or   3.   The   benefit   of peg-interferon  α -
2b over  interferon  α -2b  was  most
apparent in patients with genotype 1 or 4.13-15,22
The predominant HCV genotypes in Indonesian donor 
population were 1b (57.8%), 2a (17.2%), and 3b 
(10.9%).23 The most frequent genotype in our study was 
also genotype 1. For risk factor of HCV infection, 
previous studies have shown that the main risk factor for 
infection by genotypes 1a and 3a is intravenous drug use 
and the main risk factor for infection by genotypes 1b and 
2 is blood transfusion.24 HCV infections transmission 
from intravenous drug use is rising.24 Our study also 
showed that the most frequent HCV infection 
transmission was drug abuse.
Biochemical response at the end of treatment and 24th
week of follow up were 80% and 76.7% respectively. 
Compared to our reference study, McHutchinson et al,11
showed lower biochemical response, i.e. 34% at 24th week 
after treatment.
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In the other study25 with same population setting 
(Indonesian), but in relapsed case after previous 
interferon therapy, BR at the end of treatment and at 
24th weeks after treatment was 75% and 75% 
respectively. Biochemical responses were higher in 
HCV type non-1 non-4 than in types 1 and 4.
Many factors has been defined in predicting long-
term response of interferon therapy such as sex, age, 
body mass, index, interferon dose, duration of 
treatment, viral RNA level, and liver histology.16 In 
this trial, the suspected predictor factors were HCV 
genotype, viral load, age, and body mass index.
Hematological changes occurred during treatment 
and follow up period were anemia and neutropenia. 
Increased bilirubin level is also reported in other 
previous trials. Anemia and neutropenia in this case 
may be related to ribavirin. Ribavirin administered at 
doses of 1,200 - 1,600 mg per day can cause anemia 
and reduced T cells; whereas neutropenia was mostly 
related to interferon. Others symptoms occurred in this 
study were similar to the potential adverse events of 
interferon alpha/pegylated interferon which has been 
previously reported.10-15,19 There were no serious 
adverse event occurred in this trial. In several study, 
the adverse effect profile appears to be similar between 
interferon α -2b and pegylated interferon α -2b, 
although the frequency of certain adverse effect may 
vary. In the study done by Carrat et al,22 peg-interferon 
α -2b and interferon α -2b showed similar tolerability 
although dose modification for clini-cal and biological 
events were more frequent with peg-interferon.Cost 
analysis for this in-Asia-manufactured interferon 
alpha-2b also have showed lower treatment cost (1 : 2 
compare to in-Western-manufactured inter-feron α -2b; 
1:6 compare with pegylated interferon α - 2b).26
CONCLUSION
In conclusion, the present study demonstrates that 
the efficacy and safety of combination therapy of 
this in-Asia-manufactured interferon α -2b and 
ribavirin showed good result if we compared to other 
study of in-Western-manufactured interferon α
combined with ribavirin with similar baseline 
patients characteristics and treatment procedure. 
Therefore, this in-Asia-manu-factured interferon α -
2b can be used as an prospective alternative for 
chronic hepatitis C treatment.
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